Advancements In Targeted mRNA Delivery

mRNA has broad potential as a therapeutic. The clinical translation of mRNA therapeutics has been made possible through advances in the design of mRNA manufacturing and intracellular delivery methods. However, broad application of mRNA is still limited by the need for improved delivery systems.

Now available On-Demand, Cell & Gene Live guests Dr. Murat Kalayoglu, CEO of Cartesian Therapeutics and Walter Strapps, Ph.D., CSO of Gemini Therapeutics and Co-Founder and CEO of Carver Biosciences explain the delivery of mRNA-based therapeutics and the specific challenges, opportunities, and advancements in delivering mRNA therapeutics clinically.